As an alternative to public neoantigen vaccines, we proposed that the introduction of both neoantigen epitopes and MHC molecules into tumor cells through novel approaches would generalize the application of neoantigen vaccines to extend their therapeutic benefit in the clinic. This evidence concerns the gene HLA-C and neoplasm.